Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study

Overview of attention for article published in Cardio-Oncology, July 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 13 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,556 followers.

RT @BrJCardiol: Cardiotoxicity is an adverse effect of trastuzumab (TRA) in treating HER2+ breast cancer.A study (n=127) suggests that conc…

03 Aug 2019

Reply Repost Favourite

RT @BrJCardiol: Cardiotoxicity is an adverse effect of trastuzumab (TRA) in treating HER2+ breast cancer.A study (n=127) suggests that conc…

03 Aug 2019

Reply Repost Favourite

Cardiotoxicity is an adverse effect of trastuzumab (TRA) in treating HER2+ breast cancer.A study (n=127) suggests that concurrent use of a RAAS inhibitor during TRA treatment may provide a protective effect and warrants further investigation.https://t.co/y

02 Aug 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.